Catalyst Pharmaceuticals Competitors and Similar CompaniesClear all
Alnylam's competitors and similar companies include Olpha.
 Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Olpha Olpha (formerly known as Olainfarm) is a company engaged in the development and manufacture of pharmaceutical products. | |
Founding Date | Founding Date 2002 | Founding Date 1972 |
Type | Type Public | Type Private |
Tags | ||
Locations | Locations Olaine, LV HQ | |
Employees | Employees 1,32324% increase | Employees 2,191 |
Financial | ||
Revenue (est.) | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) €122.2m (FY, 2020) |
Cost of goods | Cost of goods $677.2m (FY, 2025) | Cost of goods €44.5m (FY, 2020) |
Gross profit | Gross profit $3b (FY, 2025) | Gross profit €80.1m (FY, 2020) |
Net income | Net income $313.7m (FY, 2025) | Net income €9.5m (FY, 2020) |
For sources of this data, please see the company profile
View Company Profiles
Olpha
HQ
Olaine, LV
Employees
2,191
Olpha (formerly known as Olainfarm) is a company engaged in the development and manufacture of pharmaceutical products.
View company